C5aR Program

CCX168 targets the chemo-attractant C5a receptor, or C5aR, which binds to a biologically activated fragment of the complement protein known as C5a. Chemo-attractant receptors are related to the chemokine receptor family and similarly regulate the migration of certain types of inflammatory cells. The chemokine system is more likely a more recent evolutionary branch of other chemo-attractant systems in the body such as the complement system. The complement system includes the protein c5a, which under certain conditions has pro-inflammatory effects. CCX168 targets the chemo-attractant C5a receptor, or C5aR, which binds to a biologically activated fragment of the complement protein known as C5. C5aR is thought to play a role in a range of inflammatory and autoimmune diseases such as AAV, psoriasis and lupus.

We completed a Phase I clinical trial for CCX168 in 40 healthy patients, which showed that CCX168 was well tolerated at doses up to 100mg.

We initiated a Phase II proof-of-concept clinical trial in AAV in the fourth quarter of 2011 and expect to complete this clinical trial by the end of 2012. If this clinical trial is successfully completed, GSK may exercise its option to further develop and commercialize CCX168.

^ Return to Top